Investors

EKF specialises in diagnostics and biotechnology patient-centric solutions

Pebble

Empowering decision-making in point-of-care testing and life sciences applications

EKF is a leading global diagnostics and biotechnology company specialising in the development, production, and distribution of innovative medical technologies and patient-centric solutions.

Welcome to our investor relations pages, where you can find official investor-focused news, reports, and presentations.

At EKF, our mission is to improve global healthcare by providing innovative solutions that empower medical professionals and enhance patient outcomes.

We are dedicated to developing and delivering high-quality, reliable, cost-effective tools and technologies that enable the early detection, accurate diagnosis, therapeutic development, and effective monitoring of conditions and diseases.

Through our commitment to excellence, collaboration, and customer satisfaction, we aim to make a positive impact on the lives of individuals and the healthcare industry by advancing the fields of point-of-care and life sciences.

EKF Diagnostics Holdings plc is an AIM-listed company based in Penarth, near Cardiff in the UK. We have manufacturing sites in the US and Germany and partner with a distribution network to sell our products in over 120 countries.

EKF Diagnostics Holdings plc is subject to the City Code on Takeover and Mergers, as published by the Takeover Panel and updated from time to time.

RNS (Regulatory News Service)

This section provides access to EKF Diagnostics Holdings PLC's Regulatory News Service (RNS) announcements, including investor updates, product news, and significant company developments, ensuring stakeholders are informed of the latest official communications.

Find out more

Share Price and Performance Data

This section provides EKF Diagnostics Holdings PLC’s live share price information, offering real-time updates and historical performance data, as well as the latest trades, helping investors and others stay informed about market trends and the company’s stock performance.

Find out more

Company Information (AIM Rule 26)

This section provides critical corporate information required for AIM Rule 26 compliance, including details about EKF Diagnostics Holdings PLC’s business, directors, governance, shareholder structure, and significant shareholders, ensuring transparency for investors.

Find out more

Corp Governance and Committees

This section outlines EKF Diagnostics Holdings PLC's corporate governance framework, including board responsibilities, committee structures, compliance with governance codes, internal controls, and shareholder relations, ensuring accountability and transparency for investors.

Find out more

Directors and Advisors

This section offers profiles of EKF Diagnostics Holdings PLC's key directors and advisors, detailing their professional backgrounds and roles within the company. It also includes information on the company's nominated advisors, auditors, and other essential advisors.

Find out more

Documents and Reports

This section provides essential documents and reports for investors, including financial statements, investor presentations, and shareholder communications, offering comprehensive insights into EKF Diagnostics Holdings PLC's corporate and operational activities.

Find out more

Point-of-care

EKF develops and manufactures point-of-care medical devices and tests (in-vitro diagnostics (IVD)) that can be used at or near the patient’s location. Designed to provide quick and accurate results, these tests enable healthcare professionals to make rapid decisions.

Find out more

Life Sciences

EKF develops and supplies reagents, enzymes, and other components used in the research, biotechnology, and pharmaceutical industries. Dedicated to supporting clinicians, scientists and researchers with high-quality materials for use in industrial and life sciences applications.

Find out more

Central Laboratory

EKF develops and provides a range of devices, tests, and media for high-throughput, accurate analysis in central laboratory settings. Our advanced technology ensures reliable results that support healthcare professionals with the precise diagnostics required on a large scale.

Find out more

Investor Relations

Walbrook PR
Tel: +44 (0)20 7933 8780
Email: ekf@walbrookpr.com

Performance highlights 2023

£52.6m

Revenue

£24.4m

Gross profit before exceptionals

£10.4m

Adjusted EBITDA

Annual Report 2023

Fraud alert

If you are approached by someone offering to buy your EKF shares at a considerable premium to the market price, please do not engage with them, they are operating an advance fee fraud, where you will be asked to make a payment up front in order to make the transaction happen. If you *do* make such a payment, they will just come back for more.

Sign up for EKF investor news and communications